Literature DB >> 17492061

The pre-travel consultation - an overview.

Tony Gherardin1.   

Abstract

BACKGROUND: Australians are great travellers and the need for travel health advice can be a common presentation in general practice. General practitioners should be an important source of accurate and up-to-date information and provide appropriate travel medicine services.
OBJECTIVE: This article aims to highlight the prerequisites and underlying principles for good travel medicine practice, define the method of risk analysis at the travel medicine consultation, and discuss the main components of service provision. DISCUSSION: Good travel medicine service implies being able to provide accurate, up-to-date advice about health risks for travellers and appropriate provision of selected vaccines, medications, medical kits and travel health products. The travel medicine consultation is the opportunity to make a risk assessment for individual travellers based on detailed analysis of the medical history, the itinerary and other information, in order to tailor advice and treatment. General practitioners should work within their abilities and refer complex cases to travel medicine specialists.

Mesh:

Year:  2007        PMID: 17492061

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  3 in total

1.  Pharmaceutical care model to assess the medication-related risks of travel.

Authors:  Ian M Heslop; Michelle Bellingan; Richard Speare; Beverley D Glass
Journal:  Int J Clin Pharm       Date:  2014-10-01

2.  Health Problems Encountered by Short-Term European Volunteers in a Nongovernmental Organization in Cambodia.

Authors:  Jaime Barrio-Cortes; Claudia Rojas-Muñoz; Miguel Ángel Acosta-Benito; Ángela Hidalgo-Baz; Ángel Vicario-Merino; María Teresa Beca-Martínez; Montserrat Ruiz-López
Journal:  Am J Trop Med Hyg       Date:  2022-01-10       Impact factor: 3.707

3.  Patients with Chronic Diseases Who Travel: Need for Global Access to Timely Health Care Data.

Authors:  Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2022-04-26       Impact factor: 5.814

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.